The EMA has recommended label expansions for Inaqovi, Opdivo, and Venclyxto, broadening treatment options in AML, Hodgkin lymphoma, and CLL.
Data from multiple studies have demonstrated the efficacy of Venclexta/Venclyxto in treating relapsed or refractory chronic lymphocytic leukemia, according to Roche. Data from multiple studies have ...
The approval is based on results from the Phase III VIALE-A study as well as the Phase Ib M14-358 clinical trial The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie ...
AbbVie’s Venclyxto is now available on the National Health Service in England via the Cancer Drugs Fund for patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL), on the ...
- Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to ...
The European Commission (EC) has approved Roche and AbbVie’s Venclyxto in combination with azacitidine and decitabine for the treatment of newly diagnosed acute myeloid leukaemia (AML) patients who ...
VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, ...
(RTTNews) - AbbVie (ABBV) announced five-year follow-up results from the phase 3 CLL14 trial, finding that more than 60 percent of patients with previously untreated chronic lymphocytic leukemia or ...
In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall ...
Roche Holding AG RHHBY announced new data from the phase III MURANO study on Venclexta/Venclyxto (venetoclax) in patients with previously treated chronic lymphocytic leukemia (CLL) at the American ...
VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results